Navigation Links
NIAID and Chinese officials sign agreement to foster TB research in China's Henan province
Date:4/28/2009

Officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and from China's Henan Provincial Bureau of Health will meet in Zhengzhou, China, on April 29 to sign an implementation arrangement intended to foster research on tuberculosis, including clinical research on new treatments for multidrug-resistant tuberculosis (MDR TB). The Henan Provincial Bureau of Health and the NIAID plan to develop jointly a collaborative TB research program at the Henan Provincial Chest Hospital.

"The emergence of drug-resistant strains of tuberculosis in China and elsewhere around the world is deeply concerning to public health officials everywhere," says NIAID Director Anthony S. Fauci, M.D. "The implementation arrangement is an important step toward what we expect will be a fruitful collaboration between U.S. and Chinese investigators. It also confirms our shared commitment to finding new ways to lessen the burden of tuberculosis."

NIAID Principal Deputy Director Hugh Auchincloss, M.D., will attend the signing ceremony. "The new initiative linking Chinese and U.S. investigators in the battle against TB is most welcome, especially in light of the recent call by the World Health Organization for expanded international research to combat this devastating disease," Dr. Auchincloss says.

According to the latest available figures from WHO, about 1.3 million people in China developed active TB disease in 2007. Researchers at the new center will carry out several projects, including clinical trials of new drugs or drug combinations designed to treat MDR TB and extensively drug-resistant TB (XDR TB). The WHO estimates that about 5 percent of newly diagnosed TB cases in China are multidrug-resistant, while 26 percent of previously but incompletely treated TB cases are multidrug-resistant. Drug-sensitive strains of TB usually can be treated successfully with a combination of antibiotics, but the lack of potent and affordable second-line TB drugs makes treating MDR and XDR TB extremely difficult. In addition to research leading to new MDR and XDR TB treatment approaches, the investigators also expect to work together to develop improved methods for rapid and accurate diagnosis of drug-sensitive and drug-resistant TB.


'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. NIAID describes research priorities to fight drug-resistant tuberculosis
6. NIAID to advance B-cell approach to HIV vaccines
7. NIAID creates HIV vaccine discovery branch
8. NIAID awards contracts to search for protein markers of disease
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID honors AIDS activist Martin Delaney
11. High alcohol consumption increases stroke risk among Chinese men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor the ... brings together top non-profit leaders, ultimate organizations, and coaches from around the US. The ... Area Disc Program Director of Youth and Education, describes this year YUCC as “an ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for ... kids and adults with muscular dystrophy, ALS and related diseases that severely limit ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... ... 2016 , ... Give To Cure today announced that it is ... Give To Cure’s campaign that is crowdfunding clinical trials to help find cures faster ... through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, ... common cancer in women worldwide, accounting for 16% of ... number of women diagnosed with breast cancer has increased ... deaths has declined due to earlier diagnosis and better ... in the past four decades, especially with increasing usage ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology: